Status:
COMPLETED
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
Lead Sponsor:
Institute for Neurodegenerative Disorders
Collaborating Sponsors:
Boehringer Ingelheim
United States Department of Defense
Conditions:
Parkinson Disease
Parkinsonian Syndrome
Eligibility:
All Genders
30+ years
Phase:
PHASE2
Brief Summary
Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the cou...
Detailed Description
Brain imaging will be conducted three times during this study. Study participants will travel to IND for \[123I\]ß-CIT and SPECT imaging (scan 1). Subjects will be randomized to no treatment, treatmen...
Eligibility Criteria
Inclusion
- 30 years or older at time of Parkinson Disease (PD) diagnosis
- clinical diagnosis of PD of equal to or less than 7.5 years
- Normal laboratory screening
Exclusion
- Participant is pregnant
- Participant has atypical or drug induced PD
- Participant has significant dementia
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT00096720
Start Date
February 1 2004
End Date
May 1 2007
Last Update
September 29 2010
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Pacific Neuroscience Medical Group
Oxnard, California, United States, 93030
2
Colorado Neurology, PC
Englewood, Colorado, United States, 80113
3
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States, 06510
4
University of Florida Movement Disorders Center
Gainesville, Florida, United States, 32610